ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2023
Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Open access · hybridAbstract read
In one paragraph
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Modelling the impact of mass drug administration with ivermectin or moxidectin on human onchocerciasis when there is sub-optimal response of parasites to treatment.Research square · 2026Article
- Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021-2023: results of screening for clinical trials of moxidectin versus ivermectin.Parasites & vectors · 2026Article
- Modelling of onchocerciasis-associated skin and ocular disease and the impact of ivermectin treatment.Communications medicine · 2026Article
- Modelling the effects of immigration on the re-introduction of onchocerciasis.Parasites & vectors · 2026Article
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Reaching elimination of onchocerciasis transmission with long-term vector control and ivermectin treatment in Togo.Nature communications · 2025Article
- Usability, acceptability, and cost of the SD BIOLINE Ov16 rapid diagnostic test for onchocerciasis surveillance in endemic communities in the middle belt of Ghana.PLoS neglected tropical diseases · 2025Article
- Modelling transmission thresholds and hypoendemic stability for onchocerciasis elimination.PLoS computational biology · 2025Article
- Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in Cameroon between 1971 and 2020.PLoS neglected tropical diseases · 2025Article
- Neglected Tropical Diseases and Female Infertility: Possible Pathophysiological Mechanisms.Journal of tropical medicine · 2025Review
- The Impact of Onchocerciasis Elimination Measures in Africa: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Modelling onchocerciasis-associated epilepsy and the impact of ivermectin treatment on its prevalence and incidence.Nature communications · 2024Article
- Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- New Tools and Nuanced Interventions to Accelerate Achievement of the 2030 Roadmap for Neglected Tropical Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs againstPharmaceutics · 2024Article
- Presumed Onchocerciasis Chorioretinitis Spilling over into North America, Europe and Middle East.Diagnostics (Basel, Switzerland) · 2023Article
- Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study.BMC infectious diseases · 2023Article
- Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 16 institutions in 15 countries.
Klodeta KuraLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.ORCID 0000-0002-0008-1440
Philip MiltonLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.
Jonathan I D HamleyLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.
Martin WalkerLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.
Didier K BakajikaExpanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN), African Regional Office of the World Health Organization (WHO/AFRO/ESPEN), Brazzaville, Democratic Republic of Congo.
Eric M KanzaProgramme Nationale de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CTP), Ministère de la Santé Publique, Kinshasa, Democratic Republic of the Congo.
Nicholas O OpokuDepartment of Epidemiology and Biostatistics, School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.
Hayford HowardLiberia Institute for Biomedical Research (LIBR), Monrovia, Liberia.
Maurice M NigoInstitut Supérieur des Techniques Médicales de Nyankunde, Bunia, Democratic Republic of the Congo.
Sampson AsareGlycoScience Research, Brookings, SD 57006, USA.
George OlipohPrecious Minerals Marketing Company, National Assay Centre, Technical Department, Diamond House, Accra, GA-143-2548, Ghana.
Simon K AttahDepartment of Medical Microbiology, University of Ghana Medical School, College of Health Sciences, Accra, Ghana.
Germain L MambanduInspection Provinciale de la Santé de la Tshopo, Kisangani, Democratic Republic of the Congo.
Kambale Kasonia KennedyDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Kambale KatalikoCentre de Santé CECA 20 de Mabakanga, Beni, Nord Kivu, Democratic Republic of the Congo.
Mupenzi MumbereMedicines Development for Global Health, 18 Kavanagh Street, Southbank, Victoria 3006, Australia.
Christine M HalleuxUNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva 27, Switzerland.
Adrian HopkinsNeglected and Disabling Diseases of Poverty Consultant, Gravesend, Kent DA11 OSL, UK.
Annette C KueselUNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva 27, Switzerland.
Sally KinradeMedicines Development for Global Health, 18 Kavanagh Street, Southbank, Victoria 3006, Australia.
Maria-Gloria BasáñezLondon Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London W2 1PG, UK.ORCID 0000-0001-5031-3361
NIHR Imperial Biomedical Research Centre · GBCenter for Global Development · USUniversity of Geneva · CHAccra Technical University · GHBrookings Institution · USCentre Hospitalier et Universitaire de Brazzaville · CGDrugs for Neglected Diseases Initiative · CHInstitut Supérieur de Technique Médicale · CDMinistère De La Santé · BFMinistry of Public Health · CDPopulation Council · INSanten (Japan) · JPUniversity of Ghana · GHUniversity of Health and Allied Sciences · GHUniversity of Liberia · LRUniversity of London · GB
Funding
Medical Research Council MR/R015600/1World Health Organization 001
Abstract
Epidemiological and modelling studies suggest that elimination of
Indexed as
OnchocerciasisAfricaHumansIvermectinMacrolidesMass Drug AdministrationNeglected DiseasesIvermectinMacrolidesmoxidectinivermectinmass drug administrationMDAmodellingmoxidectinonchocerciasis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.